Skylark Bio

News

Skylark Bio has dosed the first patient in a phase 1/2 trial of SKY-GJB2, a gene therapy for the most common form of genetic deafness in children.

News

Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.